Remsima 100 mg powder for concentrate for solution for infusion
*Company:
Celltrion Healthcare Ireland Ltd.Status:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company

Updated on 26 May 2025
File name
PIL_Remsima 100 mg IV vial_en_May 2025.pdf
Reasons for updating
- Change to section 4 - possible side effects
Free text change information supplied by the pharmaceutical company
EU Product Information (PI) update for alignment with reference product.
Not known:
(…)
- Infection due to a live vaccine because of a weakened immune system.
- Problems following a medical procedure (including infectious and non-infectious problems).
Updated on 26 May 2025
File name
SmPC_Remsima 100 mg IV vial_en_v46.0_May 2025.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
EU Product Information (PI) update for alignment with reference product updates.
SmPC Section 4.4 - Others
There is limited safety experience of infliximab treatment in patients who have undergone surgical procedures, including arthroplasty. The long half life of infliximab should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on infliximab should be closely monitored for infectiousns and non-infectious complications, and appropriate actions should be taken (see section 4.8).
Updated on 09 August 2024
File name
SmPC_Remsima 100 mg IV vial_en_Aug 2024.pdf
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 18 June 2024
File name
remsima-epar-product-information_en.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 17 June 2024
File name
CT-P13 100mg_PAC(IE)_final(Egis)_30Aug22.pdf
Reasons for updating
- Add New Doc
Updated on 17 June 2024
File name
CT-P13 100mg_Leaflet(IE)_final(400x492)(Egis)_16Jan23.pdf
Reasons for updating
- New PIL for new product
Celltrion Healthcare Ireland Ltd.

Address:
26 Arrow Building, Old Belgard Road, Tallaght, Dublin, D24 ND70Medical Information E-mail:
Medinfoie@celltrionhc.comTelephone:
01 223 4026